Medical aesthetic company Evolus has announced that its neurotoxin Nuceiva has received approval for sale in Australia.
The Australian Therapeutic Goods Administration (TGA) has provided regulatory approval for Nuceiva (prabotulinumtoxinA) for aesthetic purposes. Evolus says this has significantly expanded the company’s international marketing opportunities.
David Moatazedi, president and chief executive of Evolus, commented, “We are thrilled to gain regulatory approval for Nuceiva in Australia, one of the largest market opportunities for aesthetic neurotoxins outside of the US, where we are rapidly gaining market share, and Great Britain, where we recently launched commercial operations. This approval is the latest example of our commitment to broaden our international presence, which is a key component to reaching our aspiration of $500 million in total revenue by 2028.”
